Received Aug 20, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
HCP reported that a patient who received their first dose of GARDASIL 9 in January 2023 missed their second dose. The patient went to the pharmacy today, 08/15/2025, to get their second dose. This is when the missed dose was identified. No symptoms r; No symptoms reported.; This spontaneous report was received from a pharmacist regarding a 31-year-old patient of unknown gender. The patient's medical history, historical drugs, known drug allergies, concurrent conditions, and concomitant therapies were not reported. On 09-Jan-2023, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), suspension for injection, 0.5 mL (route of administration, lot # and expiration date were not reported). The patient Missed their next dose, but then on 15-Aug-2025 (also reported as today), the patient went to pharmacy to receive their second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), suspension for injection, 0.5 mL (route of administration, lot # and expiration date were not reported), both doses were given as prophylaxis. This is when the missed dose was identified. No symptoms reported. No additional information provided. Lot # is being requested and will be submitted if received.